Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BIOFLOW-III Hungary Satellite Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01892917
Recruitment Status : Terminated (Sponsors Decision. The collected data are available in a significant proportion and sufficiently enough for an adequate analysis.)
First Posted : July 8, 2013
Last Update Posted : October 12, 2017
Sponsor:
Information provided by (Responsible Party):
Biotronik Hungária Kft.

Tracking Information
First Submitted Date July 2, 2013
First Posted Date July 8, 2013
Last Update Posted Date October 12, 2017
Actual Study Start Date September 2012
Actual Primary Completion Date September 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: July 2, 2013)
Target Lesion Failure (TLF) [ Time Frame: 12 months ]
Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), Emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR)
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT01892917 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: October 11, 2017)
  • Target Lesion Failure [ Time Frame: 6 and 18 months ]
    Any target lesion
  • Target Vessel Revascularization (TVR) [ Time Frame: 6, 12 and 18 months ]
    Any repeat revascularization of the target vessel
  • Target Lesion Revascularization (TLR) [ Time Frame: 6, 12 and 18 months ]
    Any repeat revascularization of the target lesion
  • Stent Thrombosis [ Time Frame: 6, 12 and 18 months ]
    Definite, possible and probable
  • Clinical Device Success [ Time Frame: At time of intervention ]
    Clinical Device Success
  • Clinical Procedural Success [ Time Frame: During the hospital stay to a maximum of the first seven days post index procedure ]
    Clinical Procedural Success
Original Secondary Outcome Measures
 (submitted: July 2, 2013)
  • Target Lesion Failure [ Time Frame: 6 and 18 months ]
  • Target Vessel Revascularization (TVR) [ Time Frame: 6, 12 and 18 months ]
    Any repeat revascularization of the target vessel
  • Target Lesion Revascularization (TLR) [ Time Frame: 6, 12 and 18 months ]
    Any repeat revascularization of the target lesion
  • Stent Thrombosis [ Time Frame: 6, 12 and 18 months ]
  • Clinical Device Success [ Time Frame: At time of intervention ]
  • Clinical Procedural Success [ Time Frame: During the hospital stay to a maximum of the first seven days post index procedure ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title BIOFLOW-III Hungary Satellite Registry
Official Title BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Hungary
Brief Summary This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
Detailed Description For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedural success. However, the medium to long-term complications range from rather immediate elastic recoil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30%-50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS), designed to address the limitations of PTCA, reduced the angiographic and clinical restenosis rates in de novo lesions compared to PTCA alone and decreased the need for CABG. BMS substantially reduced the incidence of abrupt artery closure, but restenosis still occurred in about 20%-40% of cases, necessitating repeat procedures. The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by adding an antiproliferative drug (directly immobilised on the stent surface or released from a polymer matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly reduced the incidence of restenosis and resulted in a better safety profile as compared to BMS with systemic drug administration. These advantages and a lower cost compared to surgical interventions has made DES an attractive option to treat coronary artery disease. This observational registry is designed to investigate and collect clinical evidence for the clinical performance and safety of the Orsiro Drug Eluting Stent System in an all-comers patient population in daily clinical practice
Study Type Observational
Study Design Observational Model: Other
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population All-comers patient population with all subjects requiring coronary revascularization with a Drug Eluting Stent (DES)
Condition
  • Coronary Artery Disease
  • Myocardial Ischemia
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Terminated
Actual Enrollment
 (submitted: July 2, 2013)
2000
Original Estimated Enrollment Same as current
Actual Study Completion Date December 31, 2016
Actual Primary Completion Date September 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Symptomatic coronary artery disease
  • Subject has signed informed consent for data release
  • Subject is geographically stable and willing to participate at all follow-up assessments
  • Subject is ≥ 18 years

Exclusion Criteria:

  • Subject did not sign informed consent for data release
  • Pregnancy - Known intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media
  • Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained
  • Currently participating in another study and primary endpoint is not reached yet
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Hungary
Removed Location Countries  
 
Administrative Information
NCT Number NCT01892917
Other Study ID Numbers G1217
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Biotronik Hungária Kft.
Study Sponsor Biotronik Hungária Kft.
Collaborators Not Provided
Investigators
Principal Investigator: Béla Merkely, Prof. Semmelweis University
PRS Account Biotronik Hungária Kft.
Verification Date October 2017